KRAS and non-small cell lung carcinoma: Results obtained from non-small cell lung cancer (NSCLC) cells with varying EGFR and kristen rat sarcoma (KRAS) statuses indicated that NSCLC cell lines possess a heterogeneous metabolic profile, which could facilitate metabolically targeted therapy for NSCLC patients through identification and stratification (Mendes et al., 2023).